Helioson’s DAC (Degrader Antibody Conjugate) technology has been selected for preclinical studies at the 2026 American Association for Cancer Research (AACR) Annual Meeting and will be presented as Late-Breaking abstract. The full text of the abstract will be posted at 3:00 PM ET on Friday, April 17th. 

About AACR

The AACR Annual Meeting, one of the largest oncology research conferences globally, highlights forefront research and clinical progress in oncology, attracting interest from cancer researchers worldwide. The event is scheduled to take place from April 17th to 22nd, 2026, in San Diego, CA, USA.

Title: DAC-002, a novel IKZF1/3 MGD-CD38 degrader-antibody conjugate for MM treatment

Category: Late-Breaking

Presentation Number: LB049 (Section 52)

Session Time: April 19, 2026, 2:00 PM - 5:00 PM

Link：

https://www.abstractsonline.com/pp8/#!/21436/presentation/11405

About Helioson

Shanghai Helioson Pharmaceutical Co., Ltd. was established in Oct. 2021, located in Pujiang Smart Plaza, Minhang District, Shanghai. The company is dedicated to developing innovative drugs with the focus on clinical value and in-depth insight into disease mechanisms. Relying on the cutting-edge technology platforms (Protein Steady-state and DAC) to drive the development of differentiated and globally-valuable drugs, Helioson’s pipeline comprises a growing number of molecular glue /PROTAC programs on oncology and auto-immune diseases.